Finerenone reduces heart failure events in patients with HFpEF
Nov 26, 2024 · 1. In this randomized controlled trial of patients with heart failure and mildly decreased or preserved ejection fraction, finerenone treatment was associated with lower rates of worsening heart failure events. 2. Finerenone treatment was not associated with an increase in serious adverse events. Evidence Rating Level: 1 (Excellent) Study Rundown: Finerenone, a nonsteroidal mineralocorticoid ...
Amivantumab plus lazertinib improves survival in EGFR-mutated …
Nov 27, 2024 · 1. In this randomized trial, amivantamab-lazertinib led to significantly longer progression-free survival than osimertinib therapy for mutated advanced non-small-cell lung cancer (NSCLC). 2. Amivantamab-lazertinib showed superior efficacy to osimertinib as first-line therapy for epidermal growth factor receptor (EGFR) mutated advanced NSCLC. Evidence Rating Level: 1 (Excellent) Study Rundown ...
Paretic limbs suffer greater loss of bone mineral density following ...
Dec 4, 2024 · 1. BMD may differ on paretic and nonparetic sides in stroke patients with a history of falling and balance deficits Evidence Rating Level: 2 (Good) There is an increased risk of fracture due to poststroke osteoporosis. These injuries particularly affect the hip. However, current recommendations rarely recommend bone mineral density (BMD) measurements as a follow-up
Point of care C-reactive protein testing may be useful in guiding ...
Dec 6, 2024 · 1. C-reactive protein (CRP)-point-of-care tests can be used to guide antibiotic prescribing in primary care for patients with acute exacerbations of COPD with no reduction in patient outcome Evidence Rating Level: 1 (Excellent) About 80% of patients presenting with acute exacerbations of chronic obstructive pulmonary disease (AECOPD) to primary care are often given antibiotics that
Axonal injury may occur up to 9 years prior to symptom onset in ...
Dec 3, 2024 · 1. Multiple sclerosis patients can sustain axonal injury up to 9 years before symptom onset. 2. Until symptom onset, physical and mental well-being are comparable between affected and unaffected individuals. Evidence Rating Level: 3 (Average) Multiple sclerosis (MS) has an unclear mechanism and onset with physiological changes occurring well …
Lentiviral gene therapy prevents functional deterioration in …
Nov 21, 2024 · In-Depth [prospective cohort study]: This prospective cohort study investigated the efficacy and safety of eli-cel gene therapy as a treatment for cerebral adrenoleukodystrophy. Patients were eligible if they had a confirmed diagnosis of cerebral adrenoleukodystrophy through biochemical and genetic testing, exhibited characteristic gadolinium enhancement on brain MRI, had a neurologic function ...
Tirzepatide reduces obstructive sleep apnea symptoms and …
Oct 10, 2024 · 1. In this randomized controlled trial, in patients with both moderate-severe obstructive sleep apnea (OSA) and obesity, it was found that tirzepatide treatment reduced the occurrence of apneas and hypopneas. 2. Tirzepatide treatment was associated with reduced body weight and sleep apnea-associated cardiovascular risk factors. Evidence Rating Level: 1 (Excellent) Study Rundown: OSA, resulting ...
Invasive treatment not superior to medical therapy in older adults …
Dec 10, 2024 · 1. In this randomized controlled trial, in older adults with non-ST-segment elevation myocardial infarction (NSTEMI), invasive treatment did not significantly reduce the composite risk of cardiovascular death or nonfatal MI compared to conservative treatment. 2. There were fewer occurrences of fatal or nonfatal MI in patients in the invasive-strategy group than in the conservative-strategy group.
Influenza vaccination may reduce secondary infection spread …
Dec 1, 2024 · 1. Influenza vaccination was associated with a reduced risk of secondary influenza infections among household contacts, with an estimated effectiveness of 21%. Evidence Rating Level: 2 (Good) Influenza vaccinations are recommended for all individuals aged 6 months and older in the United States for the prevention of influenza infection. However, while the effectiveness of influenza
RAMOSE Phase II trial finds promising results for osimertinib and ...
Dec 10, 2024 · 1. Treatment of patients with tyrosine kinase inhibitor (TKI)-naïve epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) with osimertinib and ramucirumab resulted in a significantly longer progression-free survival (PFS) compared with osimertinib alone. Evidence Rating Level: 1 (Excellent) Study Rundown: The current standard of care for patients with advanced EGFR ...